BioNTech (BNTX)
(Delayed Data from NSDQ)
$86.82 USD
+2.57 (3.05%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $86.83 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
BioNTech SE Sponsored ADR (BNTX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$111.00 | $171.00 | $94.00 | 31.75% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for BioNTech SE Sponsored ADR comes to $111.00. The forecasts range from a low of $94.00 to a high of $171.00. The average price target represents an increase of 31.75% from the last closing price of $84.25.
Analyst Price Targets (14)
Broker Rating
BioNTech SE Sponsored ADR currently has an average brokerage recommendation (ABR) of 2.47 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.47 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, five are Strong Buy, representing 33.33% of all recommendations. A month ago, Strong Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/BNTX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 9 | 9 | 9 | 9 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.47 | 2.47 | 2.47 | 2.47 | 2.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | Evercore Partners | Cory Kasimov | Not Available | Hold |
4/17/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
4/16/2024 | SVB Securities | Daina M Graybosch | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Yaron Werber | Hold | Hold |
3/27/2024 | UBS | Eliana Merle | Hold | Hold |
3/21/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
3/21/2024 | Canaccord Genuity | William Maughan | Strong Buy | Strong Buy |
3/20/2024 | Not Identified | Not Identified | Hold | Hold |
2/28/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
10/16/2023 | Not Identified | Not Identified | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.47 |
ABR (Last week) | 2.47 |
# of Recs in ABR | 15 |
Average Target Price | $111.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -1.92 |